LENZ Therapeutics, Inc.
LENZ
$7.34
$0.050.69%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 19.71% | -87.30% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 19.71% | -87.30% | |||
| Cost of Revenue | 157.42% | -- | |||
| Gross Profit | -29.49% | -90.64% | |||
| SG&A Expenses | 13.44% | 43.62% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 14.94% | 27.60% | |||
| Operating Income | -14.75% | -103.65% | |||
| Income Before Tax | -15.58% | -114.93% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -15.58% | -114.95% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -15.58% | -114.95% | |||
| EBIT | -14.75% | -103.65% | |||
| EBITDA | -14.78% | -104.43% | |||
| EPS Basic | -14.54% | -97.45% | |||
| Normalized Basic EPS | -14.54% | -97.43% | |||
| EPS Diluted | -14.54% | -97.45% | |||
| Normalized Diluted EPS | -14.54% | -97.43% | |||
| Average Basic Shares Outstanding | 0.91% | 8.87% | |||
| Average Diluted Shares Outstanding | 0.91% | 8.87% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||